Microneedling Plus the Universal Peel For Acne Scarring

Englewood Hospital and Medical Center

Status: Completed

Conditions: Acne Scarring

Treatments: Drug: Universal Peel; Drug: Post-Universal Peel Skin Care; Drug: Post-Microneedling Skin Care; Procedure: Microneedling

Study type: Interventional

Funder types: Other

Identifiers

NCT02174393

E-14-555

Details and patient eligibility

About

Acne is a prevalent disorder mostly witnessed in adolescents, but can be seen in adults. Early treatment is imperative to reduce acne scarring which can appear with atrophic lesions, and depending on the skin type, significant erythema (redness) or post-inflammatory hyperpigmentation. A multi-modality approach to treatment is necessary when dealing with the aforementioned types of lesions. Pharmacologic management is essential, but safe procedural therapies are also necessary specifically with darker skinned individuals.

Percutaneous collagen induction therapy (PCIT) is a non-invasive treatment achieved by using a micro-needling device, which is safe and effective in causing "micro-wounds" into the dermis thereby initiating wound healing followed by collagen production. This is an ideal treatment for acne scarring, re-texturizing of the skin, and hyperpigmentation for all skin types . Currently there are very few studies evaluating the safety and efficacy of microneedling and chemical peels in skin types III-VI.

The aim of this study is to evaluate the effects of the combination of microneedling and chemical peel for the treatment of acne scars in skin types III-VI.

Enrollment: 15 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject > 18 and < 60 years of age.
• Subject has skin type III, IV, V, or VI as defined by the Fitzpatrick Classification Scale.
• Subject has acne scarring as defined by the Goodman and Baron Grading System.

Exclusion criteria

• Subject currently has moderate to severe acne on the face.
• Subject has an active infection.
• Subject is pregnant or lactating.
• Subject has a history of a bleeding disorder.
• Subject is taking an anti-coagulant.
• Subject has a history of keloidal tendency.
• Subject has received ablative or non-ablative laser treatments in the previous 6 months.
• Subject has taken Accutane within the previous 3 months.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Microneedling Plus Universal Peel

Experimental group

Description:

(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each. Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11.

Treatment:

Drug: Post-Universal Peel Skin Care

Drug: Post-Microneedling Skin Care

Procedure: Microneedling

Drug: Universal Peel